LAUSR

Background Modern pain medicine divided chronic pain as nociceptive, neuropathic, central sensitisation (CS) and mixed pain. CS syndromes are a group of disorders characterised by chronic non-neuropathic and non-nociceptive pain(.1 Central sensitisation inventory (CSI) suggest the tool generates reliable and valid data that quantify the severity of several symptoms of CS.2 Objectives Hand pain in RA, OA, and FMS have different features. The aim of this study was to show the role of CS pain in these patients. Methods Totally 151 patients with chronic hand pain (56 RA, 45 OA, and 50 FMS) were included. CSI was used for evaluation of CS.2,3 CSI consists of 2 parts: CSI-A scoring 0–100 and CSI-B including 10-CS related syndromes (restless leg, chronic fatigue, fibromyalgia, temporomandibular disorders, migraine/tension type headache, irritable bowel, multiple chemical sensitivity, whiplash, anxiety/panic attack, and depression). Results Sixteen patients (28.57%) had active (DAS28 ≥2.6) RA. Disease activity was not related with CSI-A and CSI-B scores. Rheumatoid hands was less painful compared with them of OA and FMS (p<0.001). The CS pain was detected in most of the patients with FMS, compared with OA and RA patients (p<0.001). Similarly, CSI-A score was the highest in patients with FMS group (p<0.001) and similar in both OA and RA groups (p>0.05). CS-related syndromes were also detected in both RA and OA groups, but less than FMS group (p<0.005). The numbers of CS syndromes were similar in both RA and FMS (p=0.084) and higher than OA group (p=0.036). Table 1 shows the demographic and pain parameters in all groups. CSI-A score was correlated with VAS-pain score (r=0.364, p<0.001).Abstract AB0342 – Table 1 The comparisons of groups 1.RA 2.OA 3.FMS P1–3 P2–3 Age(mean±SD) 54.52±10,33 61.2±9.67 45.22±8.6 0000 0000 Female% %83.92 %88.88 % 94 0.564 0370 DAS28 2.21±0.66 VAS 4.09±2,27 6.78±1.70 8.00±1.8 0000 0001 CSI-A (+)% %41.07 %62.22 %94 0000 0000 CSI-A 38.43±16.2 43.6±13.1 58.92±14.78 0000 0000 CSI-B (+)% %60 %28.88 %100 0000 0000 CSI-B 1.30±1.6 0.51±1.05 1.98±1.2 0000 0000 Restless leg %19.64 %4.44 %8 0101 0477 Chronic fatigue %16.07 %2.22 %6 0131 0360 Fibromyalgia %14.28 %2.22 %100 0000 0000 TMD %23.21 %17.77 %0 0000 0132 Migraine/TTH %12.5 %2.22 %30 0032 0231 İrritable bowel %5,3 %2.22 %4 0742 0621 Multi-chemical s. %3,57 %0 %4 0908 0175 Whiplash injury %7.14 %0 %2 0212 0340 Anxiety/panic %10.71 %2.22 %18 0403 0030 Depression %16.07 %15.55 %28 0161 0215 Conclusions Central sensitisation should be considered in patients with chronic persistent pain, not only having FMS, but also half of the patients having RA and OA. It is not a rare phenomenon and if it is exists, effective pain management strategies could be needed in addition to the specific pharmacologic treatment. References [1] O’Leary H, et al. Nervous System Sensitization as a Predictor of Outcome in the Treatment of Peripheral Musculoskeletal Conditions: Pain Pract2017;17(2):249–266. [2] Neblett R, et al. The CSI. The Journal of Pain2013;14(5):438–45. [3] Düzce E. SS Ölçeğinin Türkçe Geçerlilik&Güvenilirliği. Trakya FTR Uzmanlık Tezi2017. Disclosure of Interest None declared